secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2021-10-27T23:59:59+00:00
Accession:  0001157523-21-001258
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva Q3 revenues $3.9B (-2% YoY), non-GAAP EPS $0.59 vs $0.58; reaffirms FY guidance
--------------------------------------------------------------------------------

- GAAP diluted EPS $0.26 on net income $292M (vs loss $4.349B in Q3 2020).
- Non-GAAP diluted EPS $0.59 on net income $651M (up from $0.58).
- Free cash flow $795M; operating cash flow $529M.
- FY 2021 outlook: revenue $16.0-16.4B, adj. EBITDA $4.8-5.1B, EPS $2.50-2.70, FCF $2.0-2.3B.
- Announced collaboration with MODAG GmbH for movement disorder products; issued Sustainability-Linked Bond.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000115752321001258/0001157523-21-001258-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000115752321001258/a52515881.htm
  HTML page:      https://secwatch.observer/filing/0001157523-21-001258

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer